Annual Report 2015 Active Biotech AB (publ)

Active Biotech's Annual Report 2015 is now available for download at www.activebiotech.com.

The Annual Report will only be digitally distributed. The English version will be available within short.

 
LUND, Sweden, April 29, 2016 -- 
Active Biotech AB (publ)
 
Tomas Leanderson
President & CEO

For further information, please contact:
Hans Kolam, CFO
Tel +46 (0)46 19 20 44
 

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, SILC, ANYARA and paquinimod projects. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was provided to the media for publication on April 29, 2016 at 10:00 a.m. 

Annual Report 2015 Active Biotech AB (publ) http://hugin.info/1002/R/2007443/742090.pdf

HUG#2007443